semaglutide from hims Wegovy maker ends partnership with & Hers Hims & Hers warns it

Oral hypoglycemic agent

Rotate injection sites and apply a cold compress after injecting to reduce irritation

Semaglutides fat-burning properties are backed by a number of high-quality studies: Semaglutide may help bring blood sugar to normal levels through the incretin effect

Opportunities like this don't last

Effects of retatrutide on body composition in people with type 2 diabetes

This move positioned Roche to compete in the metabolic disease arena, leveraging Carmots small molecule platforms to diversify beyond oncology.[3] (2023): AstraZenecas Acquisition of CinCor Pharma Though primarily targeting hypertension, AstraZenecas US$1.8 billion buyout of CinCor included a nod toward combinational potential with metabolic therapies, signaling broader interest in cardiometabolic synergies.[4] (2024, 2025): Pfizers Strategic Reassessment and Potential for Acquisitions After halting internal development of its oral GLP-1 candidate due to tolerability concerns, Pfizer has publicly stated its interest in acquiring external GLP-1 assets